Survivin as a Potential Target for Cancer Therapy

Asian Pac J Cancer Prev. 2015;16(15):6187-91. doi: 10.7314/apjcp.2015.16.15.6187.

Abstract

In 1997 for the first time, survivin was described by Amborsini et al. as an anti-apoptotic protein. Subsequent studies revealed that survivin is a multifunctional protein that plays critical roles in several crucial cell processes such as apoptosis, cell cycle, chromosome movement, mitosis and cellular stress responses. Moreover, it's over- expression in cancer cells versus normal cells is associated with chemotherapy resistance, increased tumor recurrence, and shorter patient survival. All of these features make survivin a promising target for cancer therapy. Here, we review the potential characteristics of survivin as a tumor marker.

Publication types

  • Review

MeSH terms

  • Apoptosis*
  • Biomarkers, Tumor* / metabolism
  • Genetic Therapy
  • Humans
  • Inhibitor of Apoptosis Proteins / antagonists & inhibitors*
  • Inhibitor of Apoptosis Proteins / genetics
  • Inhibitor of Apoptosis Proteins / metabolism*
  • Molecular Targeted Therapy
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism*
  • Neoplasms / therapy
  • Survivin
  • Transcription, Genetic / drug effects
  • Up-Regulation

Substances

  • BIRC5 protein, human
  • Biomarkers, Tumor
  • Inhibitor of Apoptosis Proteins
  • Survivin